Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Fast Forward

First Genetic Disease Screening Kit For Consumers Gets FDA Approval

23andMe, the genetic testing service co-founded by Anne Wojcicki, has won landmark approval to administer tests for risk of developing 10 hereditary illnesses. In a new ruling, the Food and Drug Administration reversed its 2013 decision to deny the company approval.

Included among the conditions it screens are Parkinson’s Disease, Alzheimer’s Disease, celiac disease and Gaucher Disease –- a rare ailment suffered mostly by Ashkenazi Jews, which results in bone and joint pain, spleen issues and potential neurological damage.

23andMe offers a package in which consumers provide a DNA sample to the company and for $199 get a report breaking down their ethnic ancestry and risk for a host of diseases.

Vox notes that this makes it “the first company to sell regulator-approved genetic predisposition tests directly to consumers.”

FDA officials, while approving the company’s plans, warned that genetic testing is not the final word on whether a person will develop a given illness. “It is important that people understand that genetic risk is just one piece of the bigger puzzle, it does not mean they will or won’t ultimately develop a disease,” Jeffrey Shuren, head of the agency’s Center for Devices and Radiological Health, wrote in a statement.

Contact Daniel J. Solomon at solomon@forward.com or on Twitter @DanielJSolomon

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly. 

— Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at editorial@forward.com, subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.

Exit mobile version